^
Association details:
| Biomarker: | EGFR exon 20 insertion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Conmana (icotinib) (EGFR inhibitor) + Ivesa (firmonertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
25P - Furmonertinib Plus Icotinib for First-Line Treatment of EGFR-mutated Non-Small Cell Lung Cancer
Published date:
03/23/2023
Excerpt:
Ex19Del/L858R/Ex20ins 55.6%/38.9%/5.6%, CNS metastases 83.3%. Median follow-up was 230 days and the median PFS was not yet reached. The confirmed ORR assessed by investigator based on RECIST 1.1 was 88.9% (16 PR), DCR was 100% (16 PR, 2 SD). In patients with CNS metastasis the ORR was 86.7%, and the DCR was 100%. Tumor shrinkage was observed in all patients with a median best percent change of −34.3% (range: −76.1, −27.1)....Furmonertinib plus icotinib as first-line treatment showed encouraging antitumor activity and well tolerated safety profile in EGFR-mutated NSCLC.
